OR WAIT null SECS
Through a collaboration, Avantor and Cytovance Biologics will accelerate plasmid optimization and sourcing services for viral vectors and mRNA-based vaccines and therapeutics.
On May 10, 2022, Avantor announced that it had entered into an agreement with Cytovance Biologics, a contract development and manufacturing organization specializing in plasmid DNA, to manufacture research- and good manufacturing practice (GMP)-grade plasmids for viral vectors and messenger RNA (mRNA)-based vaccines and therapeutics.
Plasmid DNA is a critical process element in viral vector-based gene therapy and mRNA vaccines and therapeutics. Under the agreement, Avantor will provide access to plasmid DNA and other mission-critical inputs used in research, clinical testing, and manufacturing scale-up and commercialization while Cytovance Biologics will lend its plasmid current good manufacturing practice manufacturing capabilities.
"Demand for therapeutic biologics in the gene therapy space is increasing rapidly and will require increased manufacturing capacity and expertise,” said Ger Brophy, executive vice-president, Biopharma Production, Avantor, in a company press release. “Our collaboration with Cytovance Biologics demonstrates our commitment to cell and gene therapy biomanufacturers and will support our role in unlocking the potential these therapies hold for patients around the globe."
“Production of plasmid DNA extends our microbial capabilities to support the growth of the cell and gene therapy space. We are delighted to be working closely with Avantor to support the biopharmaceutical industry on a global level,” said Naomi Seresinhe, senior vice-president of business operations, Cytovance Biologics in the press release.